ScreenerHero

RNAC Cartesian Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cartesiantherapeutics.com
6.680USD-1.04%Mkt Cap: 202.11M $P/E: —

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimer…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap202.11M USD
Enterprise Value120.47M USD
Revenue (TTM)1.48M USD
Gross Profit-66.91M USD
Net Income (TTM)-130.30M USD
Revenue/Share0.06 USD
Last Price6.680 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees75
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.77
PEG—
EV/EBITDA-1.25
EV/Revenue81.56
P/S138.27
P/B-1.62
EPS (TTM)-5.78
EPS (Forward)-3.81
52W Range
5.60020% of range11.00
52W High11.00 USD
52W Low5.600 USD
Profitability
Gross Margin0.00%
Oper. Margin-6679.69%
EBITDA Margin0.00%
Profit Margin-4658.63%
ROE103.22%
ROA-43.96%
Growth
Revenue Growth—
Earnings Growth-8.00%
Cash Flow & Leverage
Operating CF-73.94M USD
CapEx (TTM)5.45M USD
FCF Margin-3214.65%
FCF Yield-23.49%
Net Debt-83.75M USD
Net Debt/EBITDA0.87
Balance Sheet
Debt/Equity-0.10
Current Ratio7.47
Quick Ratio7.19
Book Value/Sh-4.17 USD
Cash/Share4.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateApr 5, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.67 USD
Upside (mean)+404.0%
Target Range16.00 USD – 44.00 USD
16.00+404.0% to mean44.00
# Analysts6
Ownership
Shares Out.30.26M
Float11.49M
Insiders52.13%
Institutions29.45%
Short Interest
Short Ratio14.6d
Short % Float13.00%
Short % Out.5.96%
Shares Short1.80M
Short (prev mo.)1.87M
Technical
SMA 508.511 (-21.5%)
SMA 2007.710 (-13.4%)
Beta0.72
S&P 52W Chg16.45%
Avg Vol (30d)141.86K
Avg Vol (10d)167.92K
Technical Indicators
RSI (14)26.2
MACD-0.5015
MACD Signal-0.4059
MACD Hist.-0.0957
BB Upper9.179 USD
BB Middle7.764 USD
BB Lower6.349 USD
BB Width36.46%
ATR (14)0.4800 USD
Vol Ratio (20d)0.61x